Dr. Harty is a board-certified gastroenterologist and professor Emeritus at the University of Oklahoma College of Medicine. He has a special interest in Irritable Bowel Disease and Crohn’s. Dr. Harty completed fellowship at University of Florida. He completed a residency at the University of Virginia Hospital and earned his medical degree from Georgetown University School of Medicine.
Academic Section(s):
Digestive Diseases and Nutrition
Education:
Georgetown University School of Medicine, Washington, D.C.
MD 1968
Board Certification(s):
American Board of Internal Medicine
1972
Gastroenterology
1975
Residency:
University of Virginia Hospital, Charlottesville, VA
Internal Medicine
1971
Fellowship:
Hershey Medical Center of Pennsylvania, Hershey, PA
Gastroenterology
1973
University of Florida, Gainesville, FL
Research GI Fellowship
1973
Memberships:
American College of Gastroenterology (ACG) 2015 - Present
Clinical/Research Interests:
Irritable Bowel Disease
Crohn’s & Colitis
GI clinical trials research
Funding:
NIH & VA Research Grants, 1980-1997
Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintaenance Therapy for Moderately to Severely Active Crohn's Disease," Sponsored by Celgene, Private Grant/Contract Number: C8329001 July 25, 2019 - March 31, 2020
Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease," Sponsored by Celegene, Private Grant/Contract Number: C8329101 July 25, 2019 - March 31, 2020
Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease (RPC01-3204)," Sponsored by Celgene Corporation, Inc, Private Grant/Contract Number: C8328901 July 16, 2019 - March 31, 2020
Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis," I6T-MC-AMBG, Sponsored by Eli Lilly, Private Grant/Contract Number: C8326901 May 6, 2019 - January 31, 2020
Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis (IND# 115,243)," Sponsored by Celgene, Private Grant/Contract Number: C8319901 May 22, 2018 - January 31, 2020
Select Publications:
RNS Profile